Abstract:
The present invention relates to method and apparatus for interference control in a wireless communication system. According to an embodiment of the present invention, a method for operating a base station is provided. The method comprises receiving, from each of a first group of user equipments served by a first base station, first feedback information, the first feedback information including at least information indicative of a first precoding matrix included in a first cluster and information indicative of a second cluster that includes a second precoding matrix different from the first precoding matrix; exchanging feedback information with a second base station, wherein the second base station receives from each of a second group of user equipments served by the second base station second feedback information, the second feedback information including at least information indicative of a first precoding matrix and information indicative of a cluster that includes a second precoding matrix different from the first precoding matrix; coordinately scheduling, at least based on the first feedback information and the second feedback information, the first group of user equipments and the second group of user equipments.
Abstract:
A method and an apparatus for coordinating interference on a user equipment are provided, the user equipment is served by a serving base station and interfered by an interfering base station. The method comprises steps of: requesting for a limited access to the interfering base station; and responsive to an acknowledge message from the interfering base station, transmitting interference coordination information to the interfering base station.
Abstract:
The invention relates to compounds of formula (I) and salts thereof: Formula (I) wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).
Abstract:
The present teachings relate to compounds of Formula (I) and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R 1 , R 2 , R 3 , Y, Z, and (A) are as defined herein. The present teachings also provide methods of preparing compounds of Formula (I) and methods of using compounds of Formula (I) in treating, inhibiting, or preventing pathologic conditions or disorders mediated wholly or in part by deacetylases.
Abstract:
Embodiments of the present disclosure relate to a method and apparatus for performing UL scheduling and a method and apparatus for perform UL transmission. In an embodiment of the present disclosure, the method of performing UL scheduling comprises determining at least two modes for the UL scheduling based on the number of downlink (DL) subframes and the number of UL subframes, wherein the at least two modes indicate different scheduling time delays.
Abstract:
A guide and support apparatus( 220, 420, 520, 620, 720, 820, 820a ) is provided. The guide and support apparatus( 220, 420, 520, 620, 720, 820, 820a ) comprises: a mounting portion( 221, 421, 721 ), a support portion( 223, 423, 723 ) and a guide & lock portion( 224, 225, 424, 425, 524, 525 ), wherein the support portion( 223, 423, 723 ) extends to the guide &lock portion( 224, 225, 424, 425, 524, 525 ) and is ended at the mounting portion( 221, 421, 721 ); the mounting portion( 221, 421, 721 ) extends downward from one or two ends of the support portion( 223, 423, 723 ) and comprises a lock structure; and the guide & lock portion ( 224, 225, 424, 425, 524, 525 )extends from the support portion( 223, 423, 723 ) to a certain height. Further, a method for manufacturing the guide and support apparatus is provided.
Abstract:
Provided are methods and corresponding apparatuses for resource allocation. A method comprises calculating a respective marginal benefit difference for each of a plurality of user equipments according to an initial almost blank subframe pattern; sorting the plurality of UEs in an order based upon the initial almost blank pattern; and partitioning the user equipments into unique partitions; determining one partition that maximizes a utility function; repeatedly performing previous steps until a maximal utility function is identified; and arranging the user equipment according to the partition corresponding to the maximal utility function. With the claimed inventions, interference from a macro base station could be ameliorated and the spectrum efficiency would be enhanced due to improved resource allocation.
Abstract:
The present teachings relate to compounds of Formula (I): and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , ring A, and Z are as defined herein. The present teachings also provide methods of preparing compounds of Formula (I) and methods of use compounds of Formula (I) in treating pathologic conditions or disorders mediated wholly or in part by deacetylases.
Abstract:
The invention relates to compounds of formula (I) and salts thereof wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).
Abstract:
The invention relates to the use of compounds in the treatment of deacetylase-associated diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases.